CD105-directed approaches for the treatment of RCC have previously been explored in several clinical trials that utilized the anti-CD105 monoclonal antibody,TRC105 (21, 22).However, this passive antibody-mediated approach has, so far, offered no improved benefit over the current standards of care (21, 22, 50). Here, ENG is linked to renal cell carcinoma.